top digital currency to invest Top See results about

Real estate stocks of Hong Kong stocks weakened, and Sunac China fell more than 4%. As of press time, Sunac China (01918.HK) fell by 4.03%, Rongxin China (03301.HK) fell by 3.85%, and Longhu Group (00960.HK) fell by 2.43%.Chongda Technology: Five measures are taken to deal with the challenges and opportunities of industry development. Chongda Technology (002815) said in the online collective reception day of investors on December 12 that the company's measures to deal with the challenges and opportunities of industry development include: optimizing product structure, continuing to promote the optimization and upgrading of product structure, increasing R&D investment and market expansion in the field of high-end PCB boards, and accelerating the introduction of high-value customers and orders; Improve production efficiency and cost control; Accelerate the pace of capacity expansion, and promote the speed of capacity improvement of Dalian Plant, Zhuhai No.1 Plant and Zhuhai No.2 Plant in an orderly manner; According to market demand, adjust product price strategy in real time to improve profitability; Accelerate the construction of production base in Thailand, actively participate in international competition and cooperation, and enhance the company's visibility and influence in the global PCB market.The application direction of AI fell in early trading, with Jincai Internet falling more than 8%, followed by Tianyu Digital, Huayang Lianzhong, Fushi Holdings, Aofei Entertainment and Fengyuzhu.

Party Committee of CITIC Group: Firmly support the CPC Central Committee's decision to punish Xu Zuo. According to the news of CITIC Group official micro on December 13th, recently, the Party Committee of CITIC Group held a meeting to convey the decision of the State Supervision Commission of the Central Commission for Discipline Inspection to punish Xu Zuo. Xi Guohua, secretary and chairman of the Party Committee, presided over the meeting and made a speech, and members of the Party Committee made statements. Comrades attending the meeting unanimously expressed their firm support for the decision of the CPC Central Committee and the decision of the State Supervision Commission of the Central Commission for Discipline Inspection.The Japanese side hyped China's threat to return to the old road of military expansion. Recently, Japanese Prime Minister Shi Pomao delivered a policy address saying that Chinese aircraft carriers sailed in the waters close to Japan's territorial waters, and carrier-based aircraft conducted thousands of take-off and landing trainings in the Pacific Ocean; Based on the national security strategy, Japan will greatly strengthen its defense forces. In this regard, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that the Japanese side's hype about the so-called "China military threat" was just to cover up its usual trick of getting rid of the shackles of the peaceful constitution and taking the old road of military expansion again. As a matter of fact, the diplomatic and defense departments of China and Japan have been maintaining communication on air and sea security issues. There is absolutely no need for the Japanese side to be jittery and nervous. (CCTV)In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.

Musk moved SpaceX headquarters to the Starbase in Texas.Shenzhen started the construction of the first batch of "AI+" medical equipment professional parks. At the 2024 Shenzhen International High Performance Medical Equipment Exhibition and Innovative Medicine Exhibition held on December 12, a number of breakthrough cutting-edge technological achievements and innovative products were unveiled, and more than 200 famous medical equipment enterprises, scientific research institutions and medical institutions from home and abroad gathered to discuss cutting-edge technologies, explore innovative paths of medical equipment and help the high-quality development of the industry. In order to further seize the opportunity of artificial intelligence medical development, accelerate the digital transformation of Shenzhen's biomedical industry, gather a number of characteristic "AI+" medical equipment enterprises, and incubate a number of innovative medical equipment projects, Shenzhen started to build "AI+" medical equipment professional parks in key areas of industrial development. At this exhibition, the construction of the first batch of Shenzhen "AI+" pharmaceutical machinery professional parks, such as Baolong Biomedical Innovation and Development Pilot Zone, Nanshan Zhicheng, Hetao AI+ Biological Professional Park and Yinxing Science and Technology Park, was officially launched. Next, Shenzhen will vigorously improve the development and incubation of new quality productivity in the field of medical equipment, work together to shape the deep integration ecological pattern of "artificial intelligence+medical equipment", and accelerate the development and growth of "AI+" medical equipment industry.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)